Recurrent Genital Herpes Simplex Type 2
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Assembly BiosciencesSOUTH SAN FRANCISCO, CA
2 programs2
ABI-1179Phase 11 trial
ABI-5366Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
Assembly BiosciencesABI-1179
Assembly BiosciencesABI-5366
Clinical Trials (2)
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
Start: Dec 2024Est. completion: Jan 2026
Phase 1Active Not Recruiting
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
Start: May 2024Est. completion: Feb 2026
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space